Key result
Killed poliovirus vaccine provides equivalent protection to live poliovirus vaccine with no risk to recipients or contacts, highlighting the need to reevaluate US polio immunization policy.
Why the study?
Does the live poliovirus vaccine offer a better risk-benefit profile compared to the killed poliovirus vaccine for immunization in the United States?
Does the live poliovirus vaccine offer a better risk-benefit profile compared to the killed poliovirus vaccine for immunization in the United States?
No takes yet. Share an insight, caveat, or question.
The editorial challenges the US policy of recommending live poliovirus vaccine, arguing that the killed vaccine offers equivalent protection without the risk of vaccine-associated paralysis.
Darrell Salk (1988) conducted an editorial in Polio immunization. Live poliovirus vaccine vs. Killed poliovirus vaccine was evaluated. Killed poliovirus vaccine provides equivalent protection to live poliovirus vaccine with no risk to recipients or contacts, highlighting the need to reevaluate US polio immunization policy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: